THIS report describes the clinical, laboratory and genetic investigations of a large Negro family, many of whose members exhibit choreiform movements of early onset and nonprogressive nature. As far ...

The medications approved by the Food and Drug Administration (FDA) for treating Huntington’s disease chorea are Xenazine (tetrabenazine), Ingrezza (valbenazine) and Austedo (deuterabenazine).

A new study evaluated the efficacy and safety of the drug deutetrabenazine to control a prominent symptom of Huntington disease, chorea, which is an involuntary, sudden movement that can affect any ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

Huntington's disease is a genetic disorder that you can inherit from your parents. The symptoms of Huntington's disease typically start in a person's early 40s. Getting tested for Huntington's gene ...

Chorea is characterized by the occurrence of unwilled, irregular movements, abrupt and aimless, in one or more limbs or in the face and trunk, which unlike the movements of tics or habit spasms, ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...

Symptoms of ARF tend to present themselves 1-3 weeks after infection. A high index of suspicion for ARF must be maintained, especially because a single diagnostic tool does not exist. Thomas D. Jones ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA ® (valbenazine) capsules for the treatment of adults ...